Jencycla Tablet
NDC Package 68180-877-73

11-digit billing NDC: 68180087773 · Billing unit: EA · 28 EA per package

Package Information

Jencycla (norethindrone) tablets is 1.         IndicationsProgestin-only oral contraceptives are indicated for the prevention of pregnancy.2.         EfficacyIf used perfectly, the first-year failure rate for progestin-only oral contraceptives is 0.3%. This formulation utilizes a tablet delivery system. Marketed by Lupin Pharmaceuticals, Inc., this product is identified by NDC 68180-877 and is authorized under FDA application ANDA091323.

Identification & Billing

NDC Package Code
68180-877-73
Package Description
1 BLISTER PACK in 1 CARTON / 28 TABLET in 1 BLISTER PACK
Product Code
11-Digit Billing Format
68180087773
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
28 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Jencycla
Non-Proprietary Name
Norethindrone
Substance Name
Norethindrone
Dosage Form
Tablet - A solid dosage form containing medicinal substances with or without suitable diluents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
1.         IndicationsProgestin-only oral contraceptives are indicated for the prevention of pregnancy.2.         EfficacyIf used perfectly, the first-year failure rate for progestin-only oral contraceptives is 0.3%. However, the typical failure rate is estimated to be closer to 9%, due to late or omitted pills. Table 1 lists the pregnancy rates for users of all major methods of contraception. Table 1: Percentage of Women Experiencing an Unintended Pregnancy During the First Year of Typical Use and the First Year of Perfect Use of Contraception and the Percentage Continuing Use at the End of the First Year. United States. Emergency Contraception: Emergency contraceptive pills or insertion of a copper intrauterine contraceptive after unprotected intercourse substantially reduces the risk of pregnancy.9 (See Chapter 6.).Lactational Amenorrhea Method: LAM is a highly effective, temporary method of contraception.10 (See Chapter 18.)Source: Trussell J. Contraceptive Efficacy. In Hatcher RA, Trussell J, Nelson AL, Cates W, Kowal D, Policar M. Contraceptive Techology: Twentieth Revised Edition. New York NY: Ardent Media, 2011.Notes: % of Women Experiencing an Unintended Pregnancy within the First Year of Use % of Women Continuing Use at One Year Among couples attempting to avoid pregnancy, the percentage who continue to use a method for 1 year. Method Typical Use Among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. Estimates of the probability of pregnancy during the first year of typical use for spermicides, withdrawal, fertility awareness-based methods, the diaphragm, the male condom, the oral contraceptive pill, and Depo-Provera are taken from the 1995 National Survey of Family Growth corrected for underreporting of abortion; see the text for the derivation of estimates for the other methods. Perfect Use Among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. See the text for the derivation of the estimate for each method. (1) (2) (3) (4) No method The percentages becoming pregnant in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. Among such populations, about 89% become pregnant within 1 year. This estimate was lowered slightly (to 85%) to represent the percentage who would become pregnant within 1 year among women now relying on reversible methods of contraception if they abandoned contraception altogether. 85 85 Spermicides Foams, creams, gels, vaginal suppositories, and vaginal film. 28                  18 42 Fertility awareness-based methods 24 47    Standard Days method The Ovulation and Two Day methods are based on evaluation of cervical mucus. The Standard Days method avoids intercourse on cycle days 8 through 19. The Symptothermal method is a double-check method based on evaluation of cervical mucus to determine the first fertile day and evaluation of cervical mucus and temperature to determine the last fertile day.    TwoDay method 5 4    Ovulation method 3    Symptothermal method 0.4 Withdrawal 22 4 46 Sponge                       36    Parous women 24 20    Nulliparous women 12 9 Condom Without spermicides.     Female (fc) 21 5 41    Male 18 2 43 Diaphragm With spermicidal cream or jelly. 12 6 57    Combined pill and progestin-only pill 9 0.3 67    Norelgestromin and ethinyl estradiol patch 9 0.3 67 NuvaRing 9 0.3 67 Depo-Provera 6 0.2 56 Intrauterine contraceptives      ParaGard (copper T)      Mirena(LNg) 0.8 0.2 0.6 0.2 78 80 Implanon 0.05 0.05 84 Female sterilization 0.5 0.5 100 Male sterilization 0.15 0.10 100Jencycla Tablets have not been studied for and are not indicated for use in emergency contraception.

Regulatory & Marketing

Labeler Name
Lupin Pharmaceuticals, Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA091323
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
07-07-2020
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (68180-877). Click a package code to view its specific billing and regulatory data.

1 BLISTER PACK in 1 CARTON / 28 TABLET in 1 BLISTER PACK

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 68180-877-73 identifies a specific commercial package of 1 blister pack in 1 carton / 28 tablet in 1 blister pack of Jencycla, a human prescription drug labeled by Lupin Pharmaceuticals, Inc.. This tablet is formulated for oral use and contains norethindrone as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Lupin Pharmaceuticals, Inc. on July 07, 2020. The current certification is valid through December 31, 2026.

How is this Lupin Pharmaceuticals, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 68180087773. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 28 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
68180-877-73
11-Digit CMS (5-4-2)
68180-0877-73

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.